MentionFox
Home › Stakes › Mereo BioPharma Group plc
5%+ stakes · Schedule 13D and 13G

Mereo BioPharma Group plc: 5%+ holders

Who has reported owning 5% or more of Mereo BioPharma Group plc, from Schedule 13D and 13G filings: each holder's stake as filed, the timeline, and the purpose each 13D states, quoted.

At 5% or more2
Filings12
Latest filing2026-08-14

Mereo BioPharma Group plc has 12 Schedule 13D or 13G filings on record since 2025-08-14. 2 holders' latest filing reports 5% or more of ordinary shares. Each figure below is the holder's own, as filed, with the filing linked.

Holders

HolderPercentSharesLatestEvent date
683 Capital Management, LLC8.18%65,083,815SCHEDULE 13G, 2026-01-062025-12-29
Bank Of America Corp5.1%40,976,460SCHEDULE 13G, 2026-05-142026-03-31
Mangrove Partners IM, LLC4.9%38,952,900SCHEDULE 13G/A, 2025-11-142025-09-30
EcoR1 Capital, LLC0.6%5,000,000SCHEDULE 13G/A, 2026-08-142026-06-30
Janus Henderson Group Plc0%0SCHEDULE 13G/A, 2026-02-172025-12-31
Frazier Life Sciences Public Fund, L.P.0%0SCHEDULE 13G/A, 2026-02-132025-12-31
Northpond Ventures, LP0%0SCHEDULE 13G/A, 2026-02-172025-12-31

Timeline

FiledHolderPercentFiling
2025-08-14Janus Henderson Group Plc11.1%SCHEDULE 13G/A
2025-08-14Frazier Life Sciences Public Fund, L.P.4.1%SCHEDULE 13G/A
2025-11-14Mangrove Partners IM, LLC4.9%SCHEDULE 13G/A
2025-11-14Janus Henderson Group Plc10.2%SCHEDULE 13G/A
2026-01-06683 Capital Management, LLC8.18%SCHEDULE 13G
2026-01-09EcoR1 Capital, LLC9.4%SCHEDULE 13G
2026-02-13Frazier Life Sciences Public Fund, L.P.0%SCHEDULE 13G/A
2026-02-17Janus Henderson Group Plc0%SCHEDULE 13G/A
2026-02-17Northpond Ventures, LP0%SCHEDULE 13G/A
2026-05-14Bank Of America Corp5.1%SCHEDULE 13G
2026-05-15EcoR1 Capital, LLC8.4%SCHEDULE 13G/A
2026-08-14EcoR1 Capital, LLC0.6%SCHEDULE 13G/A

Tools for this story

Each opens in a new tab, filled in for Mereo BioPharma Group plc. With no account yet, you sign up free and land on the result.

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

Cite this page

Permanent URL: https://mentionfox.com/stakes/mereo-biopharma-group
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Mereo BioPharma Group plc 5%+ holders: 2 at 5% or more, largest 683 Capital Management, LLC 8.18%. MentionFox, 2026-09-27. https://mentionfox.com/stakes/mereo-biopharma-group